Hepatocellular Carcinoma (HCC) Clinical Trials

85 recruiting

Hepatocellular Carcinoma (HCC) Trials at a Glance

97 actively recruiting trials for hepatocellular carcinoma (hcc) are listed on ClinicalTrialsFinder across 6 cities in 26 countries. The largest study group is Phase 2 with 36 trials, with the heaviest enrollment activity in Guangzhou, Shanghai, and Hangzhou. Lead sponsors running hepatocellular carcinoma (hcc) studies include Fudan University, Seoul National University Hospital, and Zhejiang University.

Browse hepatocellular carcinoma (hcc) trials by phase

Treatments under study

About Hepatocellular Carcinoma (HCC) Clinical Trials

Looking for clinical trials for Hepatocellular Carcinoma (HCC)? There are currently 85 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hepatocellular Carcinoma (HCC) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hepatocellular Carcinoma (HCC) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 97 trials

Recruiting
Phase 1

A Phase 1 Study of the Safety and Tolerability of CTX-10726

Endometrial CancerRenal Cell Carcinoma (RCC)Hepatocellular Carcinoma (HCC)+1 more
Compass Therapeutics70 enrolled3 locationsNCT07419841
Recruiting
Phase 3

DEB-TACE vs cTACE in HCC After TIPS

Hepatocellular Carcinoma (HCC)TACETIPS+2 more
First Affiliated Hospital, Sun Yat-Sen University206 enrolled1 locationNCT07322848
Recruiting
Not Applicable

Computer Guided Microwave Liver Ablation

Hepatocellular Carcinoma (HCC)
NE Scientific INC84 enrolled2 locationsNCT07226869
Recruiting
Phase 1

Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer

Hepatocellular Carcinoma (HCC)
University of Hawaii15 enrolled2 locationsNCT07075120
Recruiting
Phase 2

A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC

Hepatocellular Carcinoma (HCC)
Second Affiliated Hospital, School of Medicine, Zhejiang University36 enrolled1 locationNCT07422753
Recruiting
Phase 2

HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)

Hepatocellular Carcinoma (HCC)
Fudan University164 enrolled1 locationNCT06860490
Recruiting

Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment

Advanced Hepatocellular Carcinoma (HCC)
Fudan University150 enrolled1 locationNCT07147101
Recruiting

AI-Assisted Staging and Treatment Decision-Making for Hepatocellular Carcinoma

Hepatocellular Carcinoma (HCC)
Beijing Tsinghua Chang Gung Hospital108 enrolled1 locationNCT07538882
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

Hepatocellular Carcinoma (HCC)
Bristol-Myers Squibb129 enrolled46 locationsNCT07291076
Recruiting
Not Applicable

Scout Dose of Resin Microspheres

Hepatocellular Carcinoma (HCC)Radioembolization
Seoul National University Hospital30 enrolled1 locationNCT07476651
Recruiting
Phase 2Phase 3

A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.

Hepatocellular Carcinoma (HCC)
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.680 enrolled2 locationsNCT07490262
Recruiting
Not Applicable

Electronic Symptom Monitoring of Patient-Reported Outcomes Among Patients With Hepatocellular Carcinoma During Immunotherapy (PRIME-HCC): Protocol for a Randomised Controlled Trial

Hepatocellular Carcinoma (HCC)
Wei Xiaoping500 enrolled1 locationNCT06938945
Recruiting
Phase 1Phase 2

Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC

Hepatocellular Carcinoma (HCC)
RayzeBio, Inc.590 enrolled13 locationsNCT06726161
Recruiting

Streamlining Radioembolization for Small HCC

Hepatocellular Carcinoma (HCC)
Seoul National University Hospital146 enrolled4 locationsNCT06979219
Recruiting

Same-day Radioembolization for Large HCC

Hepatocellular Carcinoma (HCC)
Seoul National University Hospital138 enrolled4 locationsNCT06944483
Recruiting
Phase 2Phase 3

Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)

Hepatocellular Carcinoma (HCC)
Tuen Mun Hospital106 enrolled1 locationNCT07293468
Recruiting
Phase 2

Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)

Hepatocellular Carcinoma (HCC)
Ruijin Hospital35 enrolled4 locationsNCT07331883
Recruiting
Phase 2

HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma (HCC)
Sun Yat-sen University76 enrolled1 locationNCT06737913
Recruiting
Phase 1Phase 2

Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC

Metastatic Liver CancerAdvanced Hepatocellular Carcinoma (HCC)
Beijing Biotech30 enrolled1 locationNCT07500220
Recruiting
Phase 1Phase 2

A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical Resection

Hepatocellular Carcinoma (HCC)
Yinghua Xu20 enrolled1 locationNCT07495215